A phase II study (biov-121) of clofarabine monotherapy first line in patients aged 65 years or older with acute meyloid leukemia for whom standard intensive chemotherapy is not considered suitable

AK Burnett; M Baccarani; P Johnson; J Yin; A Saunders; N Russell; Robert Hills

A phase II study (biov-121) of clofarabine monotherapy first line in patients aged 65 years or older with acute meyloid leukemia for whom standard intensive chemotherapy is not considered suitable

AK Burnett, M Baccarani, P Johnson, J Yin, A Saunders, N Russell, Robert Hills

Cancer and Genomic Sciences

Research output: Contribution to conference (unpublished) › Abstract

Original language	English
Pages	130a
Publication status	Published - 1 Jan 2006

Cite this

@conference{86d9aa8e8fc946a2b3efa99eb9705e41,

title = "A phase II study (biov-121) of clofarabine monotherapy first line in patients aged 65 years or older with acute meyloid leukemia for whom standard intensive chemotherapy is not considered suitable",

author = "AK Burnett and M Baccarani and P Johnson and J Yin and A Saunders and N Russell and Robert Hills",

year = "2006",

month = jan,

day = "1",

language = "English",

pages = "130a",

}

TY - CONF

T1 - A phase II study (biov-121) of clofarabine monotherapy first line in patients aged 65 years or older with acute meyloid leukemia for whom standard intensive chemotherapy is not considered suitable

AU - Burnett, AK

AU - Baccarani, M

AU - Johnson, P

AU - Yin, J

AU - Saunders, A

AU - Russell, N

AU - Hills, Robert

PY - 2006/1/1

Y1 - 2006/1/1

M3 - Abstract

SP - 130a

ER -